AASLD Recommendations updated

[flyinlynn]

The Recommendations for Testing, Managing, and Treating Hepatitis C have been updated Dated June 28th for all those interested.

http://www.hcvguidelines.org/full-report-view

[JimmyMose]

Thank you for the update

Just a couple of the many changes I noticed  (note recent changes are shown in yellow text highlight

AASLD/IDSA/IAS–USA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C.

http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection
accessed June 29. 2015
http://www.hcvguidelines.org/full-report/retreatment-persons-whom-prior-therapy-has-failed
accessed June 29. 2015

GT1 for Treatment-naive patients or whom prior PEG-IFN and RBV treatment has failed
for  sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight-based RBV regimen
Alternative regimens should be considered in patients with cirrhosis and HCV genotype 1a with the Q80K variant present.

GT3  
"Although the sofosbuvir plus PEG-IFN and RBV regimen has greater adverse events and requires an increase in monitoring, the shortened 12 weeks of treatment coupled with superior results makes this the recommended regimen in patients who can take IFN, until superior IFN-free options are defined."

24 weeks sofosbuvir plus RBV
"These data were confirmed in the randomized controlled BOSON trial as described above. (Foster, 2015) In the BOSON trial, this 24-week regimen had lower SVR rates than the 12-week sofosbuvir plus PEG-IFN and RBV regimen in treatment-naive patients, regardless of the presence of cirrhosis. Therefore, this is an alternative regimen for patients who cannot take IFN."

GT3 in whom prior PEG-IFN and RBV treatment has failed
"Accordingly, data from this randomized controlled trials strongly support the use of PEG-IFN in all treatment-experienced patients with HCV genotype 3 infection, including those without cirrhosis. Treatment with sofosbuvir and RBV for 24 weeks should be limited to those treatment-experienced patients with HCV genotype 3 infection with strong contraindications to retreatment with PEG-IFN."

Note Guidelines are for USA FDA approved drugs


Please visit
http://www.hcvguidelines.org/node/141
accessed June 29, 2015

How to Cite and Request Permission to Reprint or Use Content in the Guidance
How to cite the Guidance in papers
The website as a whole.
AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. $$$Insert date accessed here$$$.

A section or specific page on the website.
For example, if citing the HCV Testing and Linkage to Care section:
AASLD/IDSA/IAS–USA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. $$$Insert date accessed here$$$.

my opinion
Remember this is copyrighted material Brief quotes and reworded summary   are allowed under USA "fair use" laws.  extensive copying from original without permission is not.  opinions are also ok if noted.

Also recommend reading following link if you haven't
http://www.hcvguidelines.org/full-report/website-policies
accessed June 29, 2015

[SurfsideGal]

Thank you Flyinlynn. Appreciate the heads-up.